Metabolic effects of GH antagonism in patients with acromegaly

被引：1
作者：
Trainer, PJ [1 ]
机构：
[1] Christie Hosp NHS Trust, Manchester M20 4BX, Lancs, England
来源：
GROWTH HORMONE & IGF RESEARCH | 2003年 / 13卷
关键词：
growth hormone; acromegaly; pegvisomant; insulin-like growth factor-I; growth hormone deficiency;
D O I：
10.1016/S1096-6374(03)00073-X
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
Pegvisomant is a growth hormone (GH) receptor antagonist that represents a major advance in the treatment of acromegaly. Initial results with pegvisomant indicate this novel form of therapy to be the most effective treatment available for achieving biochemical disease control as ascertained by circulating IGF-I (C) 2003 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码：S152 / S156
页数：5
相关论文
共 17 条
  • [1] Successful treatment of resistant acromegaly with a growth hormone receptor antagonist
    Drake, WM
    Parkinson, C
    Akker, SA
    Monson, JP
    Besser, GM
    Trainer, PJ
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2001, 145 (04) : 451 - 456
  • [2] Effects of a growth hormone receptor antagonist on bone markers in acromegaly
    Fairfield, WP
    Sesmilo, G
    Katznelson, L
    Pulaski, K
    Freda, PU
    Stavrou, S
    Kleinberg, D
    Klibanski, A
    [J]. CLINICAL ENDOCRINOLOGY, 2002, 57 (03) : 385 - 390
  • [3] IMPAIRED CARDIAC-PERFORMANCE IS A DISTINCT FEATURE OF UNCOMPLICATED ACROMEGALY
    FAZIO, S
    CITTADINI, A
    CUOCOLO, A
    MEROLA, B
    SABATINI, D
    COLAO, A
    BIONDI, B
    LOMBARDI, G
    SACCA, L
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1994, 79 (02) : 441 - 446
  • [4] Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs
    Herman-Bonert, VS
    Zib, K
    Scarlett, JA
    Melmed, S
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (08) : 2958 - 2961
  • [5] Growth hormone receptor antagonists: Discovery, development, and use in patients with acromegaly
    Kopchick, JJ
    Parkinson, C
    Stevens, EC
    Trainer, PJ
    [J]. ENDOCRINE REVIEWS, 2002, 23 (05) : 623 - 646
  • [6] A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin and pancreatic polypeptide responses to oral glucose and a standard mixed meal
    Parkinson, C
    Drake, WM
    Roberts, ME
    Meeran, K
    Besser, GM
    Trainer, PJ
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (04) : 1797 - 1804
  • [7] Serum lipoprotein changes following IGF-I normalization using a growth hormone receptor antagonist in acromegaly
    Parkinson, C
    Drake, WM
    Wieringa, G
    Yates, AP
    Besser, GM
    Trainer, PJ
    [J]. CLINICAL ENDOCRINOLOGY, 2002, 56 (03) : 303 - 311
  • [8] Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant
    Sesmilo, G
    Fairfield, WP
    Katznelson, L
    Pulaski, K
    Freda, PU
    Bonert, V
    Dimaraki, E
    Stavrou, S
    Vance, ML
    Hayden, D
    Klibanski, A
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (04) : 1692 - 1699
  • [9] SJORGEN K, 1999, P NATL ACAD SCI USA, V96, P7088
  • [10] Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GH
    Thorner, MO
    Strasburger, CJ
    Wu, ZD
    Straume, M
    Bidlingmaier, M
    Pezzoli, SS
    Zib, K
    Scarlett, JC
    Bennett, WF
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (06) : 2098 - 2103
12